Figure 2

miR-3151 and outcome in younger IR-AML patients according to molecularly defined subgroups (FAVmol and UNFAVmol). (a) Overall survival according to miR-3151 expression levels in the UNFAVmol group. (b) leukemia-free survival according to miR-3151 expression levels in the UNFAVmol group. (c) cumulative incidence of relapse according to miR-3151 expression levels in the UNFAVmol group. (d) Overall survival according to miR-3151 expression levels in the FAVmol group.